Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPX-571
- Development stage
- Preclinical
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**CPX-571** is Celator Pharmaceuticals' preclinical liposomal fixed-dose combination of irinotecan and cisplatin, co-encapsulated at a 7:1 molar ratio using the CombiPlex drug-ratio delivery platform. The formulation was designed to maintain a synergistic irinotecan-to-cisplatin exposure ratio after intravenous administration. Irinotecan inhibits DNA topoisomerase I following conversion to its active metabolite SN-38, while cisplatin forms cytotoxic DNA crosslinks. CPX-571 showed superior antitumor activity versus the corresponding free-drug combination in preclinical xenograft models and was proposed for development in small cell lung cancer.
- Other names
- irinotecan + cisplatin liposome injectionliposomal irinotecan + cisplatin
02
Targets
DNATOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on CPX-571.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPX-571.